Abstract
The approval of Mifegymiso has exposed the legal and practical limitations of Health Canada’s adoption of Risk Management Plans for drugs.
| Original language | Canadian English |
|---|---|
| Publication status | Published - Apr. 25 2017 |
Publication series
| Name | Policy Options |
|---|
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 10 Reduced Inequalities -
SDG 16 Peace, Justice and Strong Institutions -
SDG 17 Partnerships for the Goals
Keywords
- abortion pill
- Mifegymiso
- risk management
- Health Canada
Disciplines
- Administrative Law
- Animal Law
- Business Organizations Law
- Civil Procedure
- Commercial Law
- Common Law
- Comparative and Foreign Law
- Constitutional Law
- Contracts
- Courts
- Criminal Law
- Criminal Procedure
- Dispute Resolution and Arbitration
- Environmental Law
- Evidence
- Family Law
- Food and Drug Law
- Health Law and Policy
- Human Rights Law
- Indigenous, Indian, and Aboriginal Law
- Intellectual Property Law
- International Humanitarian Law
- International Law
- Judges
- Jurisprudence
- Law
- Law and Gender
- Law and Politics
- Law and Race
- Law and Society
- Law of the Sea
- Legal Ethics and Professional Responsibility
- Other Law
- Privacy Law
- Property Law and Real Estate
- Public Law and Legal Theory
- Securities Law
- Tax Law
- Torts
Fingerprint
Dive into the research topics of 'Regulatory Risk Mismanagement and the Abortion Pill'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver